Intuitive Surgical (NASDAQ:ISRG) EVP Mark Brosius Sells 61 Shares of Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Mark Brosius sold 61 shares of Intuitive Surgical stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $441.60, for a total transaction of $26,937.60. Following the completion of the transaction, the executive vice president owned 581 shares in the company, valued at approximately $256,569.60. The trade was a 9.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Brosius also recently made the following trade(s):

• On Monday, October 26th, Mark Brosius sold 61 shares of Intuitive Surgical stock. The shares were sold at an average price of $451.75, for a total transaction of $27,556.75.
• On Friday, September 11th, Mark Brosius sold 25 shares of Intuitive Surgical stock. The shares were sold at an average price of $365.79, for a total value of $9,144.75.
• On Wednesday, September 9th, Mark Brosius sold 23 shares of Intuitive Surgical stock. The stock was sold at an average price of $350.20, for a total value of $8,054.60.
• On Tuesday, September 8th, Mark Brosius sold 46 shares of Intuitive Surgical stock. The shares were sold at an average price of $361.23, for a total value of $16,616.58.
• On Friday, August 21st, Mark Brosius sold 77 shares of Intuitive Surgical stock. The shares were sold at an average price of $375.57, for a total value of $28,918.89.
• On Wednesday, August 19th, Mark Brosius sold 77 shares of Intuitive Surgical stock. The stock was sold at an average price of $394.26, for a total value of $30,358.02.
• On Monday, August 17th, Mark Brosius sold 77 shares of Intuitive Surgical stock. The stock was sold at an average price of $390.67, for a total value of $30,081.59.
• On Friday, July 31st, Mark Brosius sold 28 shares of Intuitive Surgical stock. The stock was sold at an average price of $351.00, for a total value of $9,828.00.

Intuitive Surgical Trading Down 0.4%

ISRG stock traded down $1.70 during midday trading on Wednesday, hitting $444.18. The company had a trading volume of 1,844,128 shares, compared to its average volume of 2,428,209. Intuitive Surgical, Inc. has a 52 week low of $328.57 and a 52 week high of $603.88. The stock’s 50 day moving average price is $398.31 and its 200 day moving average price is $436.15. The stock has a market cap of $153.97 billion, a price-to-earnings ratio of 53.71, a PEG ratio of 3.12 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.35. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. The firm had revenue of $3.05 billion during the quarter, compared to analyst estimates of $2.91 billion. During the same quarter in the prior year, the firm posted $2.40 earnings per share. The business’s quarterly revenue was up 21.7% compared to the same quarter last year. Analysts predict that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ISRG has been the subject of several analyst reports. JPMorgan Chase & Co. increased their price target on shares of Intuitive Surgical from $450.00 to $475.00 and gave the company an “overweight” rating in a research report on Wednesday, October 21st. BTIG Research reiterated a “buy” rating and set a $454.00 target price on shares of Intuitive Surgical in a report on Wednesday, October 21st. Sanford C. Bernstein reissued an “outperform” rating on shares of Intuitive Surgical in a research note on Wednesday, August 12th. Citigroup reduced their price target on Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating on the stock in a report on Friday, July 17th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and set a $486.00 price target (down from $487.00) on shares of Intuitive Surgical in a research report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average price target of $493.54.

Hedge Funds Weigh In On Intuitive Surgical

Institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE boosted its position in Intuitive Surgical by 3.3% during the 1st quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock valued at $1,667,388,000 after acquiring an additional 116,292 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of Intuitive Surgical in the 2nd quarter worth approximately $1,335,753,000. Amundi raised its position in shares of Intuitive Surgical by 8.6% in the 1st quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock worth $1,119,448,000 after acquiring an additional 193,096 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Intuitive Surgical by 95.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock worth $970,635,000 after acquiring an additional 1,027,475 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its stake in shares of Intuitive Surgical by 3.7% in the 1st quarter. Janus Henderson Group PLC now owns 1,643,060 shares of the medical equipment provider’s stock valued at $757,489,000 after purchasing an additional 58,587 shares during the period. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.